KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non-Current Liabilities (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 12 years of Other Non-Current Liabilities data on record, last reported at $28.8 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities fell 94.65% year-over-year to $28.8 million; the TTM value through Sep 2025 reached $28.8 million, down 94.65%, while the annual FY2024 figure was $51.9 million, 89.89% down from the prior year.
  • Other Non-Current Liabilities reached $28.8 million in Q3 2025 per IONS's latest filing, down from $59.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $538.1 million in Q3 2024 and bottomed at $6.9 million in Q4 2021.
  • Average Other Non-Current Liabilities over 4 years is $241.2 million, with a median of $57.4 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 1002.65% in 2024, then crashed 94.65% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $6.9 million in 2021, then soared by 7296.14% to $513.7 million in 2023, then plummeted by 89.89% to $51.9 million in 2024, then tumbled by 44.56% to $28.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $28.8 million in Q3 2025, $59.1 million in Q2 2025, and $55.7 million in Q1 2025.